Semaglutide

Semaglutide is a modified analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone, developed by Novo Nordisk. It is available in three distinct FDA-approved forms: Ozempic (subcutaneous injection, 0.5–2 mg weekly) for type 2 diabetes, Wegovy (subcutaneous injection, 2.4 mg weekly) for chronic weight management, and Rybelsus (oral tablet, 3–14 mg daily) for type 2 diabetes.

Semaglutide is the most widely studied GLP-1 receptor agonist and has become a reference standard against which newer GLP-1-class drugs are compared. It holds FDA approval for three separate indications across two administration routes, making it the most versatile approved drug in its class.

The cardiovascular outcomes data for semaglutide is particularly notable. The SUSTAIN-6 trial (2016) demonstrated cardiovascular benefit in type 2 diabetes, and the SELECT trial (2023) extended this benefit to adults with obesity and established cardiovascular disease who do not have diabetes — making Wegovy the first obesity pharmacotherapy with a proven cardiovascular risk reduction indication. The FDA approved an additional indication for Wegovy in March 2024 to reduce the risk of serious cardiovascular events in adults with known cardiovascular disease and obesity or overweight.

Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, brain, gut, heart, and other tissues. Its effects arise from three primary pharmacological actions:

• Pancreatic effects: GLP-1 receptor activation in pancreatic beta cells stimulates glucose-dependent insulin secretion — meaning insulin is released only when blood glucose is elevated, substantially reducing hypoglycemia risk compared to sulfonylureas. Simultaneously, GLP-1 receptor activation on alpha cells suppresses glucagon secretion, further lowering hepatic glucose output.
• Gastric effects: Semaglutide slows gastric emptying, prolonging the time nutrients remain in the stomach. This produces earlier and more sustained postprandial satiety, reduces the rate of glucose absorption, and dampens postprandial glucose excursions.
• Central nervous system effects: GLP-1 receptors in the hypothalamus (arcuate nucleus and other regions) and hindbrain (area postrema) regulate appetite, satiety, and food reward signaling. Semaglutide crosses the blood-brain barrier and directly activates these central pathways, producing a sustained reduction in appetite and caloric intake that is independent of gastric emptying effects.

Semaglutide's molecular modifications relative to native GLP-1 include fatty acid conjugation (enabling albumin binding), which dramatically extends the half-life from approximately 2 minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing. For the oral formulation (Rybelsus), an absorption enhancer (SNAC) allows absorption across the gastric mucosa.

Semaglutide has the largest clinical development program of any GLP-1 receptor agonist, spanning multiple disease states and administration routes.

STEP Program (Obesity — Wegovy 2.4 mg)

• STEP-1 (NEJM 2021): 1,961 adults with obesity or overweight plus a comorbidity were randomized to semaglutide 2.4 mg or placebo weekly over 68 weeks alongside lifestyle intervention. Mean weight loss: 14.9% vs 2.4% placebo. 69.1% of semaglutide participants achieved ≥10% weight loss; 50.5% achieved ≥15%. PMID: 33567185.
• STEP-2 (Lancet 2021): Adults with type 2 diabetes achieved 9.6% mean weight loss at 2.4 mg vs 3.4% placebo at 68 weeks — confirming efficacy in a population where diabetes attenuates GLP-1 drug weight loss response. PMID: 33567182.
• STEP-3 (JAMA 2021): Semaglutide 2.4 mg plus intensive behavioral therapy: 16% mean weight loss vs 5.7% placebo at 68 weeks — suggesting additive benefit of structured behavioral support. PMID: 33625476.
• STEP-4 (JAMA 2021): Randomized withdrawal trial: participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their weight loss over the following 48 weeks, versus continued weight loss in those who stayed on treatment. This established that obesity management with semaglutide requires ongoing treatment. PMID: 33755728.

SELECT Trial (Cardiovascular Outcomes)

The SELECT trial (NEJM 2023) enrolled 17,604 adults aged ≥45 years with BMI ≥27 kg/m² and established cardiovascular disease (prior myocardial infarction, stroke, or peripheral arterial disease) who did not have diabetes. Semaglutide 2.4 mg weekly reduced the composite primary endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% versus placebo over a median follow-up of approximately 34 months. PMID: 37641582. This result formed the basis for FDA's March 2024 approval of Wegovy for cardiovascular risk reduction.

SUSTAIN Program (Type 2 Diabetes — Ozempic)

• SUSTAIN-6 (NEJM 2016): Semaglutide 0.5 mg and 1 mg reduced MACE by 26% vs placebo in adults with type 2 diabetes and high cardiovascular risk, establishing cardiovascular benefit for the Ozempic dose range. PMID: 27633186.
• SURPASS-2 (NEJM 2021): Tirzepatide at all doses was superior to semaglutide 1 mg in HbA1c reduction and weight loss over 40 weeks — the only published direct head-to-head comparison between these two drug classes.

Semaglutide's adverse event profile is consistent with the GLP-1 receptor agonist class and is well characterized across the extensive STEP and SUSTAIN trial programs.

Common Adverse Effects

• Gastrointestinal effects (most common): Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain. These are most common during dose escalation and typically resolve within weeks. Managing the escalation rate (a slower ramp-up than the approved schedule) is often used clinically to improve tolerability.
• Headache and fatigue: Commonly reported during dose escalation.
• Injection site reactions: Mild redness, pruritus, or bruising at the injection site.

Serious Adverse Effects and Warnings

• Thyroid C-cell tumors (black box warning): GLP-1 receptor agonists, including semaglutide, caused thyroid C-cell tumors in rodents. The human risk is unknown. Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been reported. Discontinue semaglutide if pancreatitis is suspected.
• Gallbladder disease: Cholelithiasis and acute cholecystitis were reported at higher rates with semaglutide versus placebo in STEP trials. Rapid weight loss increases gallstone risk.
• Increased heart rate: A mean increase of approximately 1–4 bpm in resting heart rate was observed in semaglutide trials. The clinical significance is under investigation.
• Diabetic retinopathy (Ozempic dose range): In the SUSTAIN-6 trial, a slightly higher rate of diabetic retinopathy complications was observed with semaglutide versus placebo in participants with a history of retinopathy — likely related to rapid glycemic improvement. Ophthalmologic monitoring is recommended.
• Lean mass loss: As with all significant weight-loss therapies, semaglutide produces some lean mass loss alongside fat loss. High protein intake and resistance exercise are recommended to mitigate this.
• Contraindications: Personal or family history of MTC or MEN 2; known hypersensitivity to semaglutide; pregnancy and breastfeeding.

The following reflects FDA-approved prescribing information. Dosing is managed by a prescribing clinician.

Wegovy (Obesity — 2.4 mg maintenance)

• 0.25 mg subcutaneous weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1.0 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• 2.4 mg weekly (maintenance dose)

The 17-week escalation schedule is designed to minimize gastrointestinal adverse effects. Some clinicians use a slower escalation in practice.

Ozempic (Type 2 Diabetes)

• Starting dose: 0.25 mg weekly for 4 weeks (not therapeutically effective; for tolerability)
• 0.5 mg weekly (minimum maintenance dose)
• Can increase to 1 mg weekly after 4 weeks if additional glycemic control is needed
• Maximum dose: 2 mg weekly

Rybelsus (Oral, Type 2 Diabetes)

• Starting dose: 3 mg daily for 30 days
• 7 mg daily for 30 days if additional glycemic control is needed
• Maximum dose: 14 mg daily
• Must be taken on an empty stomach with up to 4 oz of water at least 30 minutes before the first food, beverage, or other oral medications of the day

Compounding Status

Semaglutide has been the subject of extensive compounding pharmacy activity due to documented FDA-recognized shortages (2022–2024). The FDA declared the semaglutide shortage resolved in February 2024 and has issued warning letters to compounders. As of 2026, compounded semaglutide for commercial distribution is not FDA-authorized. Patients should use only branded Ozempic, Wegovy, or Rybelsus from licensed pharmacies.

• United States: FDA-approved. Ozempic (0.5–2 mg weekly) approved December 2017 for type 2 diabetes. Wegovy (2.4 mg weekly) approved June 2021 for chronic weight management. Wegovy approved March 2024 with an additional indication for cardiovascular risk reduction. Rybelsus (3–14 mg daily) approved September 2019 for type 2 diabetes.
• European Union: Ozempic approved by EMA in 2018 for type 2 diabetes. Wegovy approved by EMA in 2021 for weight management.
• Off-label prescribing: Ozempic (at its approved doses) is sometimes prescribed off-label for obesity without a formal diabetes diagnosis. This is legally permissible under physician discretion in the US but is not FDA-sanctioned for this purpose when Wegovy (a higher approved dose with the obesity indication) is available.
• Compounding: Compounded semaglutide is no longer FDA-authorized for commercial distribution as of 2024–2026. The FDA has taken enforcement action against multiple large-volume compounders.

• Ozempic / Rybelsus: Adults with type 2 diabetes mellitus to improve glycemic control, as an adjunct to diet and exercise. Ozempic also has an indication for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.
• Wegovy (weight management): Adults with an initial BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity. Indicated as an adjunct to a reduced-calorie diet and increased physical activity.
• Wegovy (cardiovascular risk reduction): Adults with established cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) and BMI ≥27 kg/m² — to reduce the risk of cardiovascular death, non-fatal MI, or non-fatal stroke. This is the first obesity drug approval for cardiovascular risk reduction in non-diabetic patients.